Compare Crispr Therapeutics AG (CRSP) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Cognizant Technology Solutions Corp — how do they compare? Crispr Therapeutics AG trades at $53.59 (market cap $4.88B), while Cognizant Technology Solutions Corp trades at $59.41 (market cap $27.03B). The key difference: Cognizant Technology Solutions Corp is far larger — about 5.5× Crispr Therapeutics AG's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Cognizant Technology Solutions Corp for 57 Days on average.
| CRSP | CTSH | |
|---|---|---|
Market Cap | $4.88B | $27.03B |
Volume | 2,861,747 | 9,883,888 |
Sector | Health | Technology |
52-Week High | $74.92 | $86.70 |
52-Week Low | $44.34 | $38.73 |
Typical Hold Time | 77 Days | 57 Days |
Enterprise Value | $3.30B | $28.08B |
Dividend Yield | — | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Cognizant Technology Solutions (CTSH) trades at $59.43, up 4.14% on the day, with a bullish technical signal from moving averages and support at $56. The company reported revenue of $21.11B in 2025, with a net income margin of 10.26%, and has beaten earnings estimates in two of the last three quarters. Recent news highlights its AI-driven initiatives and recognition as a top employer, reinforcing its competitive positioning in IT services.
CTSH presents a value opportunity with a P/E of 12.88 below sector averages, supported by stable cash flow and a consensus price target of $64.25. Risks include competitive pressures in IT services and potential volatility around the upcoming Q3 earnings report. The stock's current valuation and analyst buy ratings suggest upside potential, though investors should monitor execution on AI integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
